Advertisement
Orthopedics
Subscribe to Orthopedics
View Sample

FREE Email Newsletter

Reportlinker Adds The 2011 Blood Banking Market: US, Europe, Japan - Emerging Opportunities and Business Expansion Strategies for Suppliers

January 25, 2011 7:31 am | by Bio-Medicine.Org | News | Comments

NEW YORK, Jan. 25, 2011 /- Reportlinker.com announces that a new market research report is available in its catalogue: The 2011 Blood Banking Market: US, Europe, Japan - Emerging Opportunities and Business Expansion Strategies for Suppliers...

R-Tech Ueno Completes Phase 2a Clinical Study of RK-023 to Treat Androgenetic Alopecia

January 24, 2011 1:34 am | by Bio-Medicine.Org | News | Comments

TOKYO, Jan. 24, 2011 /- R-Tech Ueno, Ltd. is pleased to announce that the Phase 2a clinical study of RK-023 to treat androgenetic alopecia (note 1) was completed by January 21, 2011. Our company focuses on the area of no topical prescription drug in the market of androgenetic alopecia...

Novel Night Time Healing is Key to Shoulder Pain Relief From ROTATORELIEVER

January 24, 2011 1:34 am | by Bio-Medicine.Org | News | Comments

TRAVERSE CITY, Mich., Jan. 24, 2011 /- A good night's sleep and just five minutes of daily exercise are keys to reversing the debilitating cycle of shoulder pain. That's the prescription of Dr. Michael Carroll, M.D., inventor of ROTATORELIEVER ( www.rotatoreliever.com ), a patent-pending...

Advertisement

'Hot Health Topics' program hits airwaves(3)

January 21, 2011 2:39 pm | by Arizona State University | News | Comments

Tune in each week to KFNX-AM, starting Jan. 24., for the College of Nursing & Health Innovation's "Hot Health Topics," its first radio program.read more

Pervasis to Present Interim Data from Phase 1/2 Clinical Study of Novel Cell Therapy Targeting Peripheral Artery Disease at International Conference on Cell Therapy for Cardio...

January 20, 2011 5:44 am | by Bio-Medicine.Org | News | Comments

CAMBRIDGE, Mass., Jan. 20, 2011 /- Pervasis Therapeutics, Inc. today announced it will present interim data from the company's Phase 1/2 clinical study of PVS-10200, an investigational cell-based therapy under development to prevent restenosis in patients with peripheral arterial disease...

Software Quantifies Leaf Vein Networks, Enables Plant Biology Advances

January 13, 2011 10:38 am | by Georgia Tech Institute of Technology | News | Comments

By studying a plant's vein network pattern, biologists can investigate the plant's response to changing environments. To quickly examine leaves, researchers developed software that extracts information about macroscopic vein structures directly from leaf images.

Stereotaxis Announces CE Mark and First Human Case for Vdriveâ„¢(2)

January 11, 2011 3:37 am | by Bio-Medicine.Org | News | Comments

ST. LOUIS, Jan. 11, 2011 /- Stereotaxis, Inc. (Nasdaq: STXS ) announces the first successful cardiac ablation procedure with the Vdrive™ robotic navigation system as the company received CE Mark for this latest innovation.     In the first procedure with the Vdrive system,...

Study: Many ICD Patients Don & #8217;t Meet the Guidelines

January 7, 2011 12:36 pm | by U.S. Food & Drug Administration | News | Comments

Nearly 25 percent of patients who receive implantable cardioverter-defibrillators (ICDs) for primary prevention don’t meet the evidence-based criteria, a new study published in the Journal of the American Medical Association (JAMA) says.

Advertisement

Century Park Capital Partners Announces the Recapitalization of Cirtec Medical Systems, LLC(2)

January 6, 2011 7:37 am | by Bio-Medicine.Org | News | Comments

LOS ANGELES, Jan. 6, 2011 /- Century Park Capital Partners is pleased to announce that it led the recapitalization of Cirtec Medical Systems, LLC ("Cirtec") along with Charter Oak Equity and the company's founders. Cirtec is a leading provider of client focused, comprehensive medical...

New CVS Caremark Study Finds Health Information Technology May Help Promote Adherence, But More Information and Direction Needed

December 23, 2010 7:31 am | by Bio-Medicine.Org | News | Comments

WOONSOCKET, R.I., Dec. 23, 2010 /- A new study that reviews more than four decades of medical journal articles about the impact of health information technology (HIT) and electronic communications on medication adherence concludes that while there is evidence to suggest that simple...

Scott & White Finalizes College Station Land Deal

December 22, 2010 7:31 am | by Bio-Medicine.Org | News | Comments

COLLEGE STATION, Texas, Dec. 22, 2010 /- Scott & White Healthcare has acquired approximately 98 acres of undeveloped land that will be the home for a new 143-bed acute care hospital project. The property was purchased from Weingarten Realty Investors and College Station ISD. The...

Frost & Sullivan Presents the 2010 North American Enabling Technology of the Year Award for Surface Functionalization Technologies to Semprus BioSciences

December 21, 2010 7:35 am | by Bio-Medicine.Org | News | Comments

MOUNTAIN VIEW, Calif., Dec. 21, 2010 /- Based on its recent analysis of the surface functionalization technologies market, Frost & Sullivan recognizes Cambridge, Mass.-based Semprus BioSciences with the 2010 Enabling Technology of the Year Award for Surface Functionalization...

MinuteClinic Becomes First Retail Clinic Provider to Launch Partnership with National Patient Safety Foundation for Ask Me 3â„¢ Program

December 20, 2010 8:33 am | by Bio-Medicine.Org | News | Comments

WOONSOCKET, R.I., Dec. 20, 2010 /- MinuteClinic, the pioneer and largest provider of retail-based medical clinics in the United States, has entered into an agreement with the National Patient Safety Foundation to become the nation's first retail clinic provider to implement the Ask Me 3...

Advertisement

Boston researchers test treatment for autism link

December 17, 2010 9:32 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Children's Hospital Boston scientists have initiated a three-year clinical trial to test a potential treatment for Rett Syndrome, known to cause autism in girls.

First NxStage® Home Hemodialysis Patients Celebrate Seven-Year Anniversary

December 16, 2010 4:32 am | by Bio-Medicine.Org | News | Comments

LAWRENCE, Mass., Dec. 16, 2010 /- NxStage Medical, Inc. (Nasdaq: NXTM ), a leading manufacturer of innovative dialysis products, today announced that a group of its first patients are celebrating their seven-year anniversary of home hemodialysis treatment with the NxStage® System...

New Topical Research Reports by iData Research Published by MarketPublishers.com

December 16, 2010 4:32 am | by Bio-Medicine.Org | News | Comments

LONDON, Dec. 16, 2010 /- Market Publishers Ltd informs that new in-demand market research reports by iData Research have been added to its catalogue. Asia-Pacific Markets for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011 . In 2010, the Asia Pacific markets for...

New Study Classifies and Analyzes Protein-Protein Interfaces

December 15, 2010 7:33 am | by Georgia Tech Institute of Technology | News | Comments

A new study published this week suggests that there may be roughly a thousand structurally-distinct protein-protein interfaces -- and that their structures depend largely on the simple physics of the proteins.

Bionovo Announces Publication Describing How Metabolic Adaptability Contributes to the Metastasis of Tumors

December 15, 2010 4:32 am | by Bio-Medicine.Org | News | Comments

EMERYVILLE, Calif., Dec. 15, 2010 /- Bionovo, Inc. (Nasdaq: BNVI ) today announced the publication of a study entitled "CC3/TIP30 regulates metabolic adaptation of tumor cells to glucose limitation" in the journal Cell Cycle . The study describes the critical linkage between the...

Lanx, Inc. Appoints Dan Gladney Chief Executive Officer

December 15, 2010 4:31 am | by Bio-Medicine.Org | News | Comments

BROOMFIELD, Colo., Dec. 15, 2010 /- Lanx, Inc., a privately held medical device company focused on developing and commercializing innovative devices for spinal surgery, announced the appointment of Dan W. Gladney as Chief Executive Officer and as a member of the Board of Directors. He...

NewCardio Presents Results for Cardiac Safety Research Consortium Blinded Drug Safety Study

December 10, 2010 4:33 am | by Bio-Medicine.Org | News | Comments

SANTA CLARA, Calif., Dec. 10, 2010 /- NewCardio, Inc., (OTC Bulletin Board: NWCI ) a cardiovascular diagnostic solutions developer, today presented the results from a blinded drug safety study conducted by the Cardiac Safety Research Consortium (CSRC) to evaluate the performance of...

Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD811 for Pulmonary Arterial Hypertension

December 10, 2010 4:33 am | by Bio-Medicine.Org | News | Comments

SAN DIEGO, Dec. 10, 2010 /- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA ) announced today the initiation of dosing in a Phase 1 clinical trial of APD811, a novel oral drug candidate discovered by Arena that targets the prostacyclin receptor for the treatment of pulmonary arterial...

HeartWare International, Inc. Announces Pricing of Concurrent Public Offerings of Convertible Senior Notes and Common Stock

December 10, 2010 4:32 am | by Bio-Medicine.Org | News | Comments

FRAMINGHAM, Mass. and SYDNEY, Dec. 10, 2010 /- HeartWare International, Inc. (Nasdaq: HTWR, ASX: HIN) ("HeartWare") announced today the pricing of a public offering of $125 million principal amount of convertible senior notes due 2017 (the "notes") pursuant to an effective shelf...

Study Shows Novartis Drug Afinitor® Plus Hormonal Therapy Delays Disease Progression in Advanced Metastatic Breast Cancer Patients

December 9, 2010 7:33 am | by Bio-Medicine.Org | News | Comments

EAST HANOVER, N.J., Dec. 9, 2010 /- A new study shows that the addition of everolimus (Afinitor® tablets) to the hormonal therapy tamoxifen in patients with hormone-receptor positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer who have been...

Anthera Announces Update Call Regarding Vial Problems

December 9, 2010 7:32 am | by Bio-Medicine.Org | News | Comments

HAYWARD, Calif., Dec. 9, 2010 /- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH ), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it will hold a conference call to provide an update on the ongoing investigation and...

Aromatase Inhibitors Increased Risk of Heart Disease in Postmenopausal Women with Breast Cancer

December 9, 2010 5:34 am | by AACR | News | Comments

SAN ANTONIO - Postmenopausal women who take aromatase inhibitors as a treatment for breast cancer may be at an increased risk for developing cardiovascular disease, according to the results of a meta-analysis.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading